You are here

Research and Development

Mosaiques has developed a unique technology on the basis of clinical proteome analysis, enabling the early and differential detection of cardiovascular, renal, biliary and urogenital diseases. Furthermore, diagnostic tests for additional indications, such as Alzheimer's disease and nephrotoxic effects of drugs are in development. Diagnosis is accomplished by highly specific patterns of multiple simultaneously detected biomarkers (proteins/polypeptides) from patient samples obtained in a risk-free and painless procedure. Mosaiques utilizes high resolution capillary electrophoresis coupled mass spectrometry (CE-MS technology), which enables the separation of body fluids in less than one hour. Proprietary software affords the analysis of huge amounts of data within minutes.

The overall principle of this ground-breaking technology is the fact that proteins are indispensable for the function of cells and organs, as well as for all communication inside the body. They also catalyze chemical reactions and protect the body against pathogens. Thousands of proteins and peptides are involved in these processes, forming a distinct pattern, which changes with disease. Mosaiques identifies up to 6,000 of such proteins and polypeptides and subsequently generates disease specific patterns. This vast wealth of information facilitates accurate diagnosis of diseases and enables effective therapy prior to serious organ damage.

The analytical platform was found to be acceptable by FDA and EMA in 2011.